HIFN-α gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function

Gene Therapy

Volumn 20, Issue 11, 2013, Pages 1062-1069

  Jiang, W ^a   Zhang, C ^a   Tian, Z ^a   Zhang, J ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

antitumor; gene transfer; IFN A; natural killer cells

Indexed keywords

ALPHA INTERFERON; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; GRANZYME B; PERFORIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXICITY; DNA MODIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; UPREGULATION;

MUS MUSCULUS;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HEP G2 CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-ALPHA; KILLER CELLS, NATURAL; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887445313     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2013.31     Document Type: Article

References (40)

1. Roder JC, Pross HF. The biology of the human natural killer cell. J Clin Immunol 1982; 24: 249-263.
2. Miller J. The biology of natural killer cells in cancer, infection, and pregnancy. Exp Hematol 2001; 29: 1157-1168.
3. Farag SS, Caligiuri MA. Cytokine modulation of the innate immune system in the treatment of leukemia and lymphoma. Adv Pharmacol 2004; 51: 295-318.
4. Hallett WH, Murphy WJ. Natural killer cells: biology and clinical use in cancer therapy. Cell Mol Immunol 2004; 1: 12-21.
5. Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 2004; 24: 1861-1871.
6. Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 2010; 59: 1781-1789.
7. Tonn T, Becker S, Esser R, Schwabe D, Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 2001; 10: 535-544.
8. Cheng M, Zhang J, Jiang W, Chen Y, Tian Z. Natural killer cell lines in tumor immunotherapy. Front Med 2012; 6: 56-66.
9. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol 1996; 24: 406-415.
10. Maasho K, Marusina A, Reynolds NM, Coligan JE, Borrego F. Efficient gene transfer into the human natural killer cell line, NKL, using the Amaxa nucleofection systemTM. J Immunol Methods 2004; 284: 133-140.
11. Smyth MJ, Hayakawa Y, Taked K, Yagita H. New aspects of natural-killercell surveillance and therapy of cancer. Nat Rev Cancer 2002; 2: 850-861.
12. Jiang W, Zhang J, Tian Z. Functional characterization of interleukin-15 gene transduction into the human natural killer cell line NKL. Cytotherapy 2008; 10: 265-274.
13. Zhang J, Sun R, Wei H, Zhang JH, Tian ZG. Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy. Haematologica 2004; 89: 338-347.
14. Ferrantini M, Capone I, Belardelli F. Interferon-A and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007; 89: 884-893.
15. Belardelli F, Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunology 1996; 17: 369-372.
16. Gutterman JU. Cytokine therapeutics: lessons from interferon-Alpha. Proc Natl Acad Sci USA 1994; 91: 1198-1205.
17. Moschella F, Bisikirska B, Maffei A, Papadopoulos KP, Skerrett D, Liu Z et al. Gene expression profiling and functional activity of human dendritic cells induced with IFN-A-2b: implications for cancer immunotherapy. Clin Cancer Res 2003; 9: 2022-2031.
18. Cangemi G, Morandi B, DAgostino A, Peri C, Conte R, Damonte G et al. IFN-Alpha mediates the up-regulation of HLA class I on melanoma cells without switching proteasome to immunoproteasome. Int Immunol 2003; 15: 1415-2.
19. Viard-Leveugle I, Gaide O, Jankovic D, Feldmeyer L, Kerl K, Pickard C et al. TNF-A and IFN-g are potential inducers of fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Invest Dermatol 2013; 133: 489-498.
20. Moretta L, Ferlazzo G, Bottino C, Vitale M, Pende D, Mingari MC et al. Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev 2006; 214: 219-228.
21. Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007; 7: 329-339.
22. Chan JK, Hamilton CA, Cheung MK, Karimi M, Baker J, Gall JM et al. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res 2006; 12: 1859-1867.
23. Nagashima S, Mailliard R, Kashii Y, Reichert TE, Herberman RB, Robbins P et al. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood 1998; 91: 3850-3861.
24. Zhang J, Sun R, Wei H, Zhang J, Tian Z. Characterization of stem cell factor genemodified human natural killer cell line, NK-92 cells: implication in NK cell-based adoptive cellular immunother-Apy. Oncol Rep 2004; 11: 1097-1106.
25. Kamath AT, Sheasby CE, Tough DF. Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFNab and IFN-g. J Immunol 2005; 174: 767-776.
26. Nguyen KB, Salazar-Mather TP, Dalod MY, Van Deusen JB, Wei XQ, Liew FY et al. Coordinated and distinct roles for IFN-A, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol 2002; 169: 4279-4287.
27. Paquette RL, Hsu NC, Kiertscher SM, Park AN, Tran L, Roth MD et al. Interferonalpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukocyte Biol 1998; 64: 358-367.
28. Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998; 161: 1947-1953.
29. Santodonato L, DAgostino G, Nisini R, Mariotti S, Monque DM, Spada M et al. Monocyte-derived dendritic cells generated after a shortterm culture with IFN-A and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8t T-cell response. J Immunol 2003; 170: 5195-5202.
30. Tosi D, Valenti R, Cova A, Sovena G, Huber V, Pilla L et al. Role of cross-talk between IFN-A-induced monocyte-derived dendritic cells and NK cells in priming CD8t T-cell responses against human tumor antigens. J Immunol 2004; 172: 5363-5370.
31. Xie Q, Shen HC, Jia NN, Wang H, Lin LY, An BY et al. Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9 microbes. J Infect 2009; 11: 515-523.
32. Sun C, Fu B, Gao Y, Liao X, Sun R, Tian Z et al. TGF-b1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence. PLoS Pathogen 2012; 8: e1002594.
33. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990; 76: 2421-2438.
34. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC et al. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 1996; 14: 619-648.
35. Soloski MJ. Recognition of tumor cells by the innate immune system. Curr Opin Immunol 2001; 132: 154-162.
36. Riccioli A, Starace D, DAlessio A, Starace G, Padula F, De Cesaris P et al. TNF-Alpha and IFN-gamma regulate expression and function of the Fas system in the seminiferous epithelium. J Immunol 2000; 165: 743-749.
37. Spanaus KS, Schlapbach R, Fontana A. TNF-Alpha and IFN-gamma render microglia sensitive to Fas ligand-induced apoptosis by induction of Fas expression and down-regulation of Bcl-2 and Bcl-xL. Eur J Immunol 1998; 28: 4398-4408.
38. Li Z, Tuteja G, Schug J, Kaestner KH. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell 2012; 148: 72-83.
39. Sells MA, Chen ML, Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA 1987; 84: 1005-1009.
40. Grund EM, Muise-Helmericks RC. Cost efficient and effective gene transfer into the human natural killer cell line, NK92. J Immunol Methods 2005; 296: 31-36.